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Background: This study evaluated whether demographics, pre-diagnosis lifestyle habits and clinical data are associated with
the overall survival (OS) and head and neck cancer (HNC)-specific survival in patients with HNC.
Patients and methods: We conducted a pooled analysis, including 4759 HNC patients from five studies within the International
Head and Neck Cancer Epidemiology (INHANCE) Consortium. Cox proportional hazard ratios (HRs) and the corresponding 95%
confidence intervals (CIs) were estimated including terms reported significantly associated with the survival in the univariate analysis.
Results: Five-year OS was 51.4% for all HNC sites combined: 50.3% for oral cavity, 41.1% for oropharynx, 35.0% for hypopharynx
and 63.9% for larynx. When we considered HNC-specific survival, 5-year survival rates were 57.4% for all HNC combined: 54.6%
for oral cavity, 45.4% for oropharynx, 37.1% for hypopharynx and 72.3% for larynx. Older ages at diagnosis and advanced tumour
staging were unfavourable predictors of OS and HNC-specific survival. In laryngeal cancer, low educational level was an
unfavourable prognostic factor for OS (HR¼ 2.54, 95% CI 1.01–6.38, for high school or lower versus college graduate), and
status and intensity of alcohol drinking were prognostic factors both of the OS (current drinkers HR¼ 1.73, 95% CI 1.16–2.58)
and HNC-specific survival (current drinkers HR¼ 2.11, 95% CI 1.22–3.66). In oropharyngeal cancer, smoking status was an
independent prognostic factors for OS. Smoking intensity (>20 cigarettes/day HR¼ 1.41, 95% CI 1.03–1.92) was also an
independent prognostic factor for OS in patients with cancer of the oral cavity.
Conclusions: OS and HNC-specific survival differ among HNC sites. Pre-diagnosis cigarette smoking is a prognostic factor of
the OS for patients with cancer of the oral cavity and oropharynx, whereas pre-diagnosis alcohol drinking is a prognostic factor
of OS and HNC-specific survival for patients with cancer of the larynx. Low educational level is an unfavourable prognostic factor
for OS in laryngeal cancer patients.
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Introduction
Squamous cell carcinoma of the head and neck (HNC) is the sev-
enth common cancer worldwide [1], with 600 000 new cases
diagnosed each year worldwide. HNC is the eighth leading cause
of cancer death [1]. HNC includes different types of cancers, of
which the most frequent are cancers of the oral cavity, orophar-
ynx, hypopharynx and larynx.
The overall survival (OS) rate for these neoplasm has improved
over the last decades, but still differs depending on the HNC sub-
site [2]. For patients with oral cavity, oropharyngeal and hypo-
pharyngeal cancer, an improvement in the 5-year survival was
observed in most European countries, while for patients with la-
ryngeal cancer the improvement was less evident [3]. In Europe,
5-year survival rates were 45% for oral cavity, 39% for the oro-
pharynx, 25% for the hypopharynx, 59% for the larynx [3]. In de-
veloping countries, the survival for patients with these tumours is
still lower than in developed countries [4].
HNC patients are also likely to have a high chance of recur-
rence and second primary cancers involving particularly the head
and neck, lung and oesophagus [5]. Survival of patients with
HNCs and second primary cancers has been shown to be poorer
than survival of HNC patients without second primary cancers.
Second primary cancers within the head and neck region were
associated with a better prognosis than those outside this ana-
tomic region [6].
Several lifestyle factors such as tobacco smoking and alcohol
drinking, which are the main risk factors for HNC [7, 8], together
with diet [9, 10] and physical activity [11] were related with the
prognosis of these cancers [12, 13]. In addition, a recent study re-
ported that socioeconomic status (SES) was associated with sur-
vival in univariate analysis. However, the effect disappeared after
accounting for age, gender, TNM stage, smoking and alcohol [14].
To date, very few large studies have examined the role of prog-
nostic factors for HNC on survival from these neoplasms. The
aims of this study are to investigate the OS and cancer-specific
survival in a large cohort of HNC patients within the
International Head and Neck Cancer Epidemiology (INHANCE)
Consortium, and to identify independent prognostic factors for
HNC subsites.
Materials and methods
We conducted a pooled analysis using data from five studies within the
INHANCE Consortium [15]: Milan (Italy), Rome (Italy), Western
Europe involving three Italian centres [Aviano (Friuli Venezia Giulia),
Padua (Veneto), Turin (Piemonte)], Sao Paulo (Brazil) and Japan. The
studies were approved by the local ethics committees. The recruitment
was conducted from 2002 to 2005 in Aviano and Padua, from 2003 to
2005 in Turin, from 2001 to 2009 in Milan, from 2002 to 2014 in Rome,
from 2002 to 2011 and from 2011 to 2014 in Sao Paulo and from 2001 to
2005 in Japan.
In each study, patients with histologically confirmed primary squa-
mous cell carcinoma of HNCwere included.
The tumours were staged according to the tumour, node, metastasis
(TNM) classification [16] and classified into anatomic site according to the
following ICD-O-2 codes: oral cavity (C00.3–C00.9, C02.0–C02.3, C03.0,
C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C06.0–C06.2, C06.8 and
C06.9), oropharynx (C01.9, C02.4, C05.1, C05.2, C09.0, C09.1, C09.8,
C09.9, C10.0–C10.4, C10.8 and C10.9), hypopharynx (C12.9, C13.0–
C13.2, C13.8 and C13.9), oral cavity or pharynx overlapping or not
otherwise specified (C02.8, C02.9, C05.8, C05.9, C14.0, C14.2 and C14.8)
and larynx (codes C32.0–C32.3 and C32.8–C32.9).
Data collection
Information on demographics, lifetime alcohol and tobacco consump-
tion, and other selected lifestyle habits were collected by trained inter-
viewers or medical doctors. Health behaviours focused on the time
period ending 1 year before diagnosis. These data were previously pooled
andmanaged by the INHANCE consortium coordination.
Participants were followed from the date of diagnosis to the date of
death or to the end of follow-up, whichever occurred first. Death certifi-
cate data were also used for mortality, and the cause of death was coded
according to the International Classification of Diseases, Ninth Revision.
Data on tumour pathology were obtained from pathology records.
All the follow-up information collected was shared by each study with
the coordinating centre at the Universita` Cattolica del Sacro Cuore in
Rome, Italy. All data were checked for internal consistency, and clarifica-
tions were requested from the original investigators when needed.
Outcome and variables definition
The primary end point was the OS, defined as the time from the date of
initial diagnosis of HNC primary tumour to the date of death from any
cause or last follow-up. The secondary end point was the HNC-specific
survival, defined as the time from the date of initial diagnosis of HNC pri-
mary tumour to the date of death from HNC or last follow-up. With re-
spect to smoking, patients were classified as never, former or current
smokers. Frequency of tobacco consumption (never smokers,20 cigar-
ettes/day, >20 cigarettes/day) and smoking duration in years (never
smokers, 20, >20) were also calculated. With respect to alcohol drink-
ing, subjects were classified as never, former or current drinkers, and ac-
cording to alcohol consumption (none, 1 drink equivalent/day, >1
drink equivalent/day).
Statistical analysis
We used the Kaplan–Meier method to calculate the cumulative propor-
tion surviving and to plot the survival curves. We compared the survival
curves using log-rank test and Wilcoxon–Breslow–Gehan test where ap-
propriate. We used the Cox’s proportional hazards model to determine
independent predictors of OS and HNC-specific survival. We tested the
Cox proportional hazards assumption for each covariate using
Schoenfeld residuals [17]. We adjusted hazard ratios (HRs) for the OS
and HNC-specific survival for the variables that were significantly associ-
ated with the OS and HNC-specific survival in the univariate analysis.
Furthermore, in order to account for different treatment access and
types, the multivariable models were adjusted also by study centre. In the
HNC-specific survival analysis, we excluded the Japanese study because
the information on cause of death was not available. In the multivariable
analysis, for both the OS and HNC-specific survival, we excluded the
Milan study because information on tumour stage was not available. We
carried out analyses for all studies together, considering overall HNC and
individual subsites (oral cavity, oropharynx, hypopharynx, larynx). We
conducted all statistical analyses using Stata software (StataCorp. 2013.
Stata Statistical Software: Release 13. College Station, TX: StataCorp LP).
Results
A total of 4759 HNC cases were pooled from seven participating
centres. For 540 (15.7%) patients from the Brazilian centre and 21
(2.0%) patients from the Italian centre the date of diagnosis or the
date of death was not available and were therefore excluded, result-
ing in 4198 (88.2%) eligible patients in the analysis (Table 1). Most
of the patients were from the Sao Paulo study (68.9%), 24.1%
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from Italy (Milan, Rome, Aviano, Turin, Padua) and the remain-
ing 7.0% from Japan. Disease location was oral cavity in 1404
(35.6%) patients, oropharynx in 834 (21.1%) patients, hypophar-
ynx in 376 (9.5%) patients, larynx in 1332 (33.8%) patients and
oral cavity or pharynx not otherwise specified in 252 (6.0%)
patients.
Median age was 59 years (63 for Italy, 61 for Japan and 57 for
Brazil) with a higher prevalence of males (77.8%). The Italian
studies and the Japanese study were entirely composed of patients
with white and Asian ethnicity, respectively; the Brazilian study
had a higher prevalence of white ethnicity (68.8%), followed by
mulatto (18%), black (8.6%) and others (4.6) (data not shown).
Table 2 reported the median follow-up time and the number of
deaths by tumour site and study. A total of 1924 patients (45.8%)
died during the follow-up, of whom 1408 died from HNC.
Percentages of deaths from all causes in the HNC subsites were
45.2% for oral cavity, 53.5% for oropharynx, 60.1% for hypo-
pharynx and 36.2% for larynx.
Table 2. Median survival time and number of deaths by tumour site and study centre
n Follow-up time (months) Deaths Deaths from HNC
Median 1Q 3Q n % n %a
Tumour site
Oral cavity 1.404 24 11 58 635 45.2 476 35.3
Oropharynx 834 18 9 51 446 53.5 352 43.7
Hypopharynx 376 20 9 48 226 60.1 168 48.3
Larynx 1.332 42 16 75 482 36.2 304 23.2
OC, OP, HP NOS 252 27 11 71 135 53.6 108 43.4
Study centre
Milan, Italy 161 59 26 81 80 49.7 41 25.5
Rome, Italy 498 48 18 85 200 40.6 103 21.0
Western Europe
Aviano 123 87 38 99 51 41.5 40 33.1
Padua 117 61 17 97 67 57.3 50 42.7
Turin 113 79 18 100 64 56.6 48 42.5
Sao Paulo, Brazil 2.892 20 10 45 1.367 47.3 1.126 39.4
Japan 294 60 40 75 95 32.3 na
Total 4.198 27 11 63 1.924 45.8 1.408 34.7
aPercentages were calculated excluding missing values.
HNC, head and neck cancer; OC, oral cavity; OP, oropharynx; HP, hypopharynx; NOS, not otherwise speciﬁed; na, not available; 1Q, ﬁrst quartile; 3Q, third
quartile.
Table 1. Characteristics of 4198 cases of head and neck cancer from ﬁve studies participating in the International Head and Neck Cancer Epidemiology
(INHANCE) Consortium, according to tumour site
Study centre Recruitment
period
Oral cavity Oropharynx Hypopharynx Larynx OC, OP, HP NOS Total
n %a n %a n %a n %a n % n %b
Milan, Italy 2002–2009 31 19.9 9 5.8 8 5.1 108 69.2 5 3.1 161 3.8
Rome, Italy 2002–2014 88 17.9 84 17.1 23 4.7 297 60.4 6 1.2 498 11.9
Western Europe 2002–2005 121 34.9 82 23.6 30 8.6 114 32.9 6 1.7 353 8.4
Aviano 2002–2005 46 38.0 34 28.1 9 7.4 32 26.4 2 1.6 123 2.9
Padua 2002–2005 25 21.6 26 22.4 14 12.1 51 44.0 1 0.9 117 2.8
Turin 2003–2005 50 45.5 22 20.0 7 6.4 31 28.2 3 2.7 113 2.7
Sao Paulo, Brazil 2002–2014 1.017 38.3 610 23.0 268 10.1 762 28.7 235 8.1 2.892 68.9
Japan 2001–2005 147 50.0 49 16.7 47 16.0 51 17.3 0 0.0 294 7.0
Total 1.404 35.6 834 21.1 376 9.5 1.332 33.8 252 6.0 4.198 100.0
aRow percentages were calculated excluding OC, OP, HP NOS. bColumn percentages.
OC, oral cavity; OP, oropharynx; HP, hypopharynx; NOS, not otherwise speciﬁed.
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Five-year OS for all HNC sites combined was 51.4% (50.3% for
oral cavity, 41.1% for oropharynx, 35.0% for hypopharynx and
63.9% for larynx; Figure 1). When we considered the HNC-
specific survival, 5-year survival rate was 57.4% for all HNC com-
bined (54.6% for oral cavity, 45.4% for oropharynx, 37.1% for
hypopharynx and 72.3% for larynx; Figure 2). The survival differs
according to study centre: patients from the Japanese centre re-
ported the highest survival (P< 0.001) while patients from the
Brazilian centre reported the lowest survival (P< 0.0001).
The distributions of selected covariates and adjusted HRs for
all-cause mortality by tumour site and considering HNC overall are
presented in Table 3. Multivariate analysis suggested that increasing
age at diagnosis was associated with a reduced OS for HNC overall
(HR¼ 1.02, 95% CI 1.01–1.03), for oral cavity cancer (HR¼ 1.02,
95% CI 1.01–1.03), for oropharyngeal cancer (HR¼ 1.02, 95% CI
1.00–1.03) and for laryngeal cancer (HR¼ 1.03, 95% CI 1.02–1.05).
Patients with laryngeal cancer and with educational level of less
than or equal to high school had unfavourable OS when compared
with those having more than high school education (HR¼ 2.54,
95%CI 1.01–6.38).
Compared with patients with tumour stage I, patients with tu-
mour stage IV reported a reduced OS for HNC overall
(HR¼ 3.48, 95% CI 2.77–4.37), for oral cavity cancer
(HR¼ 3.81, 95% CI 2.65–5.48), for oropharyngeal cancer
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Figure 1. Kaplan–Meier unadjusted overall 5-year survival by head and neck cancer site.
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Figure 2. Kaplan–Meier unadjusted speciﬁc 5-year survival by head and neck cancer site.
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Table 3. Adjusted predictors of OS among 4198 head and neck cancer patients by tumour site
Subjectsa Oral Cavity Oropharynx Hypopharynx Larynx OC, OP, HP NS Total
n51404 n5 834 n5 376 n5 1332 n5 252 n5 4198
n % HRb 95% CI HRc 95% CI HRd 95% CI HRe 95% CI HRd 95% CI HRc 95% CI
Demographics
Age at diagnosis 4.198 1.02 1.01–1.03 1.02 1.00–1.03 1.01 1.00–1.02 1.03 1.02–1.05 1.02 1.00–1.04 1.02 1.01–1.03
Gender
Men 3.218 76.9 1.00 1.00 1.00 1.00 1.00 1.00
Women 967 23.1 0.98 0.78–1.23 1.04 0.76–1.44 0.81 0.51–1.28 0.74 0.51–1.07 0.71 0.42–1.19 1.00 0.86–1.17
Missing 13 0.3
Ethnicity
Caucasian 3.009 71.7 1.00 1.00 1.00 1.00 1.00 1.00
Black 240 5.7 1.04 0.74–1.48 1.07 0.62–1.83 0.82 0.44–1.52 1.21 0.68–2.16 1.23 0.57–2–67 1.06 0.83–1.35
Asian 317 7.6 1.42 0.53–3.86 6.14 0.75–50.31 0.56 0.36–0.86 1.80 0.24–13.53 2.20 0.53–9.17 1.21 0.64–2.29
Other 565 13.5 1.08 0.84–1.40 1.44 1.04–1.99 0.82 0.55–1.23 1.10 0.74–1.63 1.02 0.63–1.67 1.11 0.95–1.31
Missing 67 1.6
Education level
College graduate 121 3.4 1.00 1.00 1.00 1.00 1.00 1.00
High-technical
school graduate
581 16.5 1.04 0.57–1.89 1.69 0.71–3.99 1.19 0.35–4.03 2.54 1.01–6.38 1.24 0.39–3.95 1.39 0.95–2.04
Less than high school 2.828 80.1 1.04 0.60–1.82 1.74 0.76–3.95 1.96 0.62–6.17 2.32 0.95–5.66 0.83 0.30–2.32 1.37 0.95–1.95
Missing 668 15.9
Tumour characteristics
Stage
I 452 13.0 1.00 1.00 1.00 1.00 1.00 1.00
II 537 15.5 1.45 0.96–2.19 1.19 0.55–2.55 1.03 0.06–16.78 1.23 0.81–1.87 1.74 0.67–4.53 1.43 1.08–1.88
III 573 16.5 2.28 1.52–3.44 1.88 0.93–3.81 2.46 0.32–18.76 1.29 0.84–1.97 2.15 0.78–5.94 1.86 1.43–2.43
IV 1.907 55.0 3.81 2.65–5.48 3.10 1.63–5.89 5.18 0.71–37.79 2.46 1.75–3.48 4.19 1.83–9.64 3.48 2.77–4.37
Missing 729 17.4
Comorbidity
No 512 12.2% 1.00 1.00 1.00 1.00 1.00 1.00
Yes 443 10.6% 1.45 0.96–2.21 1.00 0.61–1.65 0.85 0.44–1.63 1.16 0.77–1.76 nc nc 1.15 0.91–1.46
Missing 3.243 77.3%
Cigarette smoking
Smoking status
Never smokers 400 9.7 1.00 1.00 1.00 1.00 1.00 1.00
Former 1.015 24.7 1.05 0.68–1.63 1.66 0.88–3.10 1.00 0.49–2.06 1.12 0.65–1.92 0.80 0.41–1.57 0.98 0.77–1.25
Current 2.691 65.5 1.20 0.92–1.57 1.83 1.01–3.36 1.06 0.53–2.12 1.33 0.78–2.25 0.88 0.50–1.55 1.08 0.86–1.36
Missing 92 2.2
Years of smoking
Never smokers 400 16.8 1.00 1.00 1.00 1.00 1.00 1.00
20 401 16.8 1.05 0.68–1.63 2.33 1.15–4.72 0.81 0.35–1.90 0.95 0.48–1.85 0.48 0.20–1.19 1.08 0.80–1.47
>20 1.579 66.3 1.20 0.92–1.57 1.72 0.94–3.18 1.06 0.53–2.10 1.14 0.64–2.01 0.91 0.52–1.59 1.07 0.85–1.34
Missing 187 7.3
Cigarettes per day
Never smokers 400 9.9 1.00 1.00 1.00 1.00 1.00 1.00
20 2.548 63.3 1.14 0.87–1.50 1.87 1.01–3.48 0.97 0.49–1.95 1.10 0.62–1.94 0.86 0.49–1.51 1.05 0.83–1.33
>20 1.077 26.8 1.41 1.03–1.92 1.66 0.88–3.15 1.12 0.55–2.27 1.17 0.64–2.11 0.92 0.48–1.76 1.10 0.86–1.42
Missing 173 4.1
Alcohol drinking
Drinking status
Never drinkers 575 14.0 1.00 1.00 1.00 1.00 1.00 1.00
Former 1.027 24.9 0.77 0.56–1.08 1.49 0.84–2.63 1.14 0.62–2.07 1.10 0.69–1.75 0.80 0.45–1.45 1.09 0.87–1.36
Current 2.519 61.1 1.08 0.81–1.44 1.36 0.79–2.36 1.37 0.77–2.42 1.73 1.16–2.58 0.85 0.51–1.42 1.31 1.07–1.61
Missing 77 1.8
Drinks per day
Never drinkers 575 14.9 1.00 1.00 1.00 1.00 1.00 1.00
Continued
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(HR¼ 3.10, 95% CI 1.63–5.89) and for laryngeal cancer
(HR¼ 2.46, 95% CI 1.75–3.48). Compared with never smoking
status, cigarette smoking was an unfavourable prognostic factor
for cancer of the oropharynx (current smokers, HR¼ 1.83, 95%
CI 1.01–3.36;20 years of smoking, HR¼ 2.33, 95% CI 1.15–4.72;
20 cigarette per day, HR¼ 1.87 95%CI 1.01–3.48). Taking as ref-
erence the category never smoking, smoking >20 cigarettes/day
was an unfavourable prognostic factor for cancer of the oral cavity
(HR¼ 1.41, 95%CI 1.03–1.92). Comparedwith never drinkers, al-
cohol use was associated with a reduced survival in patients with
laryngeal cancer (current drinkers, HR¼ 1.73, 95% CI 1.16–2.58;
1 drinks per day, HR¼ 1.72, 95% CI 1.12–2.63; >1 drinks per
day HR¼ 1.61, 95%CI 1.04–2.51).
The distributions of selected covariates, and the adjusted HRs
for HNCmortality are shown in Table 4. At multivariate analysis,
increasing age at diagnosis was a negative prognostic factor for
cancer of the oropharynx and larynx. Taking as reference the cat-
egory college graduates, patients with an education less than high
school reported a reduced HNC-specific survival considering
HNC overall (high-technical school graduate, HR¼ 1.48, 95% CI
1.01–2.15; less than high school, HR¼ 1.45, 95% CI 1.02–2.06).
Compared with tumour stage I, tumour stage IV was associated
with a reduced HNC-specific survival in all HNC sites except for
hypopharynx (oral cavity, HR¼ 3.42, 95% CI 2.24–5.22; oro-
pharynx, HR¼ 3.97, 95% CI 1.86–8.48; larynx, HR¼ 4.58, 95%
CI 2.69–7.80). Cigarette smoking was not associated with a
reduced HNC-specific survival in any of the HNC sites.
Compared with never drinkers, alcohol drinking was a
prognostic factor for patients with cancer of the larynx (current
drinkers, HR¼ 2.11, 95% CI 1.22–3.66; 1 drinks per day,
HR¼ 2.07, 95% CI 1.17–3.69; >1 drinks per day HR¼ 1.92,
95%CI 1.04–3.53).
Discussion
We evaluated the 5-year overall and HNC-specific survival in a
sample of 4198 HNC patients pooled from five studies including
centres in three different countries: Italy, Brazil and Japan. Five-
year OS was 51.4% and differed across HNC sites: patients
with laryngeal cancer reported the highest overall (63.9%) and
HNC-specific (72.3%) 5-year survival while patients with
hypopharyngeal cancer reported the lowest overall (35.0%) and
HNC-specific (37.1%) 5-year survival. Alcohol consumption is
not only associated with an increasing risk of laryngeal cancer [8]
but also an increasing risk of death.
These results are consistent with previous studies that investi-
gated the OS among HNC sites [2, 3, 18]. A study that investi-
gated the trends of the survival in patients with HNC reported in
the period between 2002 and 2006, a 5-year relative survival rate
of 65.9% for HNC overall. Moreover, the OS was highest among
patients with laryngeal cancer (66.8%) and lowest among patients
with hypopharyngeal cancer (33.8%) [2]. A recent multicentric
study, involving 801 HNC patients (also included in our study
representing 19% of the sample) in Italy, reported a 5-year
relative survival rate of 62% for HNC overall: 55% for oral
cavity, 53% for oropharynx, 41% for hypopharynx and 71% for
larynx [18].
The role of SES on OS in a HNC population and the relation-
ships between SES and the various clinical, demographic and so-
cial habits associated with HNC risk and survival were recently
explored in a study conducted in Canada. The authors reported
an association between SES and the OS among HNC patients.
However, this association was lost after age at diagnosis, gender,
TNM stage and smoking and alcohol status were accounted for
[14]. In this study, we reported an association between educa-
tional level and the OS for patients with laryngeal cancer and an
association between educational level and the HNC-specific sur-
vival for HNC overall. We did not have information on SES, and
used education as a proxy. We also cannot rule out confounding
by SES indicators such as income or occupation.
Several epidemiological studies have investigated the associ-
ation between cigarette smoking and alcohol consumption on
survival from HNC, reporting contrasting results [12, 13, 18–23].
A population-based study conducted in Italy and not included in
the current pooled analysis reported an association between
Table 3. Continued
Subjectsa Oral Cavity Oropharynx Hypopharynx Larynx OC, OP, HP NS Total
n51404 n5 834 n5 376 n5 1332 n5 252 n5 4198
n % HRb 95% CI HRc 95% CI HRd 95% CI HRe 95% CI HRd 95% CI HRc 95% CI
1 2.307 59.8 1.01 0.76–1.34 1.46 0.81–2.62 1.23 0.69–2.21 1.72 1.12–2.63 0.88 0.53–1.45 1.30 1.05–1.62
>1 975 25.3 1.11 0.75–1.63 1.20 0.67–2.18 1.28 0.67–2.46 1.61 1.04–2.51 0.69 0.35–1.38 1.27 1.00–1.61
Missing 341 8.1
aNumber of subject and percentages is referred to all HNC sites together.
bHR adjusted by age at diagnosis, stage, smoking status and study centre.
cHR adjusted by age at diagnosis, gender, stage, education level, smoking status, alcohol drinking status and study centre.
dHR adjusted by age at diagnosis and study centre.
eHR adjusted by age at diagnosis, gender, stage, education level, alcohol drinking status and study centre.
CI, conﬁdence interval; HNC, head and neck cancer; HR, hazard ratio; HP, hypopharynx; nc, not computable; NOS, not otherwise speciﬁed; OC, oral cavity;
OP, oropharynx. Text in bold indicates statistically signiﬁcant risk factors.
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Table 4. Adjusted predictors of head and neck-speciﬁc survival among 3904 head and neck cancer patients by tumour site
Subjectsa Oral Cavity Oropharynx Hypopharynx Larynx OC, OP, HP NS Total
n5 1257 n5 785 n5 329 n5 1281 n5 252 n53904
n % HRb 95% CI HRc 95% CI HRd 95% CI HRc 95% CI HRe 95% CI HRc 95% CI
Demographics
Age at diagnosis 3.904 1.01 1.00–1.02 1.02 1.00–1.03 1.00 0.99–1.02 1.02 1.00–1.03 1.01 1.00–1.03 1.01 1.00–1.02
Gender
Men 2.985 76.7 1.00 1.00 1.00 1.00 1.00 1.00
Women 906 23.3 1.01 0.78–1.31 1.11 0.79–1.55 0.94 0.56–1.55 0.95 0.59–1.52 0.74 0.42–1.32 1.11 0.93–1.33
Missing 13 0.3
Ethnicity
Caucasian 3.009 71.7 1.00 1.00 1.00 1.00 1.00 1.00
Black 240 5.7 1.10 0.77–1.58 1.01 0.58–1.76 0.94 0.51–1.76 1.15 0.63–2.11 1.29 0.55–3.04 1.05 0.81–1.36
Asian 317 7.6 1.38 0.44–4.37 4.86 0.59–40.23 0.33 0.05–2.35 1.49 0.19–11.46 2.50 0.57–11.08 1.25 0.61–2.55
Other 565 13.5 1.12 0.85–1.48 1.46 1.06–2.03 0.81 0.52–1.27 0.91 0.58–1.41 0.91 0.53–1.59 1.07 0.89–1.27
Missing 67 1.6
Education level
College graduate 121 3.4 1.00 1.00 1.00 1.00 1.00 1.00
High-technical
school graduate
581 16.5 1.09 0.63–1.92 1.5 0.63–3.58 1.48 0.43–5.10 2.20 0.67–7.20 2.93 0.91–9.43 1.48 1.01–2.15
Less than high school 2.828 80.1 1.03 0.62–1.70 1.72 0.76–3.92 2.47 0.78–7.78 2.00 0.63–6.32 1.25 0.45–3.84 1.45 1.02–2.06
Missing 374 9.6
Tumour characteristics
Stage
I 399 12.6 1.00 1.00 1.00 1.00 1.00 1.00
II 468 14.7 1.33 0.81–2.17 1.54 0.64–3.69 1.48 0.09–24.15 1.40 0.71–2.75 4.15 0.92–18.72 1.72 1.21–2.47
III 526 16.6 1.90 1.17–3.08 2.08 0.91–4.72 1.58 0.20–12.47 2.03 1.10–3.77 5.62 1.21–26.06 2.30 1.63–3.124
IV 1.782 56.1 3.42 2.24–5.22 3.97 1.86–8.48 3.48 0.50–25.81 4.58 2.69–7.80 10.43 2.55–42.62 4.73 3.49–6.41
Missing 729 18.7
Comorbidity
No 512 12.2% 1.00 1.00 1.00 1.00 1.00 1.00
Yes 443 10.6% 1.46 0.94–2.27 1.12 0.66–1.92 0.85 0.42–1.71 1.69 0.91–3.15 nc nc 1.25 0.94–1.64
Missing 3.243 77.3%
Cigarette smoking
Smoking status
Never smokers 331 8.7 1.00 1.00 1.00 1.00 1.00 1.00
Former 943 24.7 0.87 0.59–1.27 1.60 0.83–3.08 1.10 0.43–2.83 1.02 0.50–2.08 0.89 0.43–1.86 0.92 0.70–1.21
Current 2.538 66.6 1.08 0.78–1.48 1.52 0.81–2.86 1.18 0.47–2.94 0.90 0.45–1.80 0.89 0.47–1.66 0.93 0.72–1.21
Missing 92 2.4
Years of smoking
Never smokers 331 8.9 1.00 1.00 1.00 1.00 1.00 1.00
20 366 9.8 1.07 0.65–1.75 1.73 0.83–3.60 0.87 0.30–2.60 0.73 0.29–1.84 0.53 0.20–1.41 0.88 0.63–1.24
>20 3.024 81.3 1.06 0.77–1.47 1.43 0.76–2.69 1.19 0.48–2.95 0.97 0.46–2.03 0.93 0.50–1.72 0.92 0.71–1.19
Missing 183 4.7
Cigarettes per day
Never smokers 331 67.6 1.00 1.00 1.00 1.00 1.00 1.00
20 2.416 27.6 1.01 0.73–1.41 1.50 0.79–2.83 1.05 0.42–2.62 0.94 0.45–1.99 0.83 0.44–1.56 0.90 0.69–1.16
>20 987 4.8 1.28 0.89–1.84 1.32 0.68–2.56 1.37 0.54–3.49 0.99 0.46–2.14 1.10 0.54–2.23 0.97 0.73–1.28
Missing 170 4.4
Alcohol drinking
Drinking status
Never drinkers 500 29.8 1.00 1.00 1.00 1.00 1.00 1.00
Former 1.014 67.9 0.75 0.50–1.10 1.52 0.85–2.74 0.93 0.49–1.74 1.24 0.68–2.27 0.89 0.47–1.70 1.07 0.83–1.38
Current 2.313 2.3 1.01 0.72–1.44 1.41 0.79–2.49 1.10 0.60–2.01 2.11 1.22–3.66 0.88 0.50–1.54 1.31 1.04–1.66
Missing 77 2.0
Drinks per day
Never drinkers 500 61.4 1.00 1.00 1.00 1.00 1.00 1.00
Continued
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smoking and survival from laryngeal cancer, while no effect of al-
cohol consumption was found [20]. The same relationship was
later explored by larynx subsites, reporting cigarette smoking as
an independent prognostic factor for the cancer of the endolar-
ynx and alcohol consumption as an independent prognostic fac-
tor for cancer of the epilarynx [12]. A multicentric study
conducted in Italy reported alcohol consumption as predictor of
survival in patients with cancer of the larynx [18]. A large
population-based study conducted in Ireland found that smoking
was a strong predictor of survival in patients with cancer of the oral
cavity, pharynx and larynx, and the association was stronger in pa-
tients treated with surgery [22]. Another study conducted in Japan
found smoking as a predictor of OS but not of the HNC-specific
survival for patients with cancer of the oral cavity [19]. Moreover, a
study conducted in theUnited States highlighted the effect of smok-
ing on increasing risk of death in patients with p16-positive and
p16-negative oropharyngeal cancer [23].
In this study, we observed an increased risk of overall mortality
for smokers with cancer of the oral cavity and oropharynx and for
alcohol drinkers with cancer of the hypopharynx and larynx.
However, when we restricted the analysis to the specific mortality
due to HNC, the only prognostic factor that we found was alcohol
consumption for patients with laryngeal cancer. As observed in a
multicentric European study that investigated lifestyle habits as
prognostic factors in survival of laryngeal and hypopharyngeal can-
cer [12], the effect of smoking (and alcohol drinking) on survival
may be due to the excessivemortality of heavy smokers and alcohol
drinkers due to causes other than HNC. Furthermore, it is possible
that current smokers have stopped smoking during follow-up, and
this would lead to an underestimation of the true effect of smoking.
Limitations of this study are the lack of information on comor-
bidities when investigating the cancer-specific survival, and the
lack of information on HPV status when investigating the sur-
vival of patients with oropharyngeal cancer. Moreover, we did
not have data on patient’s behaviour after the diagnosis, which
may have affected the overall and specific survival. Despite these
limitations, our study has several strengths, including the indi-
vidual data pooled study design that led us to a large number of
HNC patients from three world regions. Due to the large sample
size, we were able to evaluate the survival in HNC subsites and to
adjust for multiple factors when estimating the prognostic factors
for specific HNC subsites.
This study showed that cigarette smoking was a prognostic
factor of the OS for patients with cancer of the oral cavity and
oropharynx, and alcohol drinking was a prognostic factor of the
OS and HNC-specific survival for patients with cancer of the
larynx. Patients with cancer of the larynx and with low educa-
tional level also had an unfavourable prognosis. Additional
studies including a large sample of patients that allow the ad-
justment for the main confounders, including comorbidities,
and the lifestyle habits after the diagnosis might define and will
highlight the differences of HNC subsites in terms of lifestyle
related prognostic factors.
Funding
The pooled data coordination team was supported by National
Cancer Institute (grant R03CA113157) and by National Institute
of Dental and Craniofacial Research (grant R03DE016611). The
S~ao Paolo study was supported by the S~ao Paulo Research
Foundation – FAPESP (GENCAPO 04/12054-9, 10/51168-0).
The Rome study was supported by Italian Association for
Research on Cancer (AIRC) – IG 2013 (contract no. 14220) and
Fondazione Veronesi (CUP: J54G13000430007). The Milan
study was supported by AIRC and Italian Ministry of Education
(PRIN 2009 X8YCBN). The Turin study and Padua study were
supported by European Community (5th Framework
Programme) (grant no QLK1-CT-2001-00182). The Japan study
was supported by Scientific Research grant from the Ministry of
Education, Science, Sports, Culture and Technology of Japan
(17015052) and grant for the Third-Term Comprehensive 10-
Year Strategy for Cancer Control from the Ministry of Health,
Labor and Welfare of Japan (H20-002). The work was supported
by the PRECeDI project (Marie Skłodowska-Curie Research and
Innovation Staff Exchange—RISE No 645740).
Table 4. Continued
Subjectsa Oral Cavity Oropharynx Hypopharynx Larynx OC, OP, HP NS Total
n5 1257 n5 785 n5 329 n5 1281 n5 252 n53904
n % HRb 95% CI HRc 95% CI HRd 95% CI HRc 95% CI HRe 95% CI HRc 95% CI
1 2.091 28.6 0.97 0.69–1.37 1.53 0.84–2.78 0.97 0.52–1.80 2.07 1.17–3.69 0.93 0.53–1.62 1.32 1.03–1.69
>1 975 9.9 0.97 0.62–1.52 1.19 0.64–2.24 1.13 0.57–2.21 1.92 1.04–3.53 0.69 0.32–1.50 1.27 0.97–1.67
Missing 338 8.7
aNumber of subject and percentages is referred to all HNC sites together.
bHR adjusted by stage, smoking status and study centre.
cHR adjusted by gender, stage, smoking status, alcohol drinking status and study centre.
dHR adjusted by study centre.
eHR adjusted by stage.
nc, not computable; CI, conﬁdence interval; HNC, head and neck cancer; HR, hazard ratio; HP, hypopharynx; nc, not computable; NOS, not otherwise speci-
ﬁed; OC, oral cavity; OP, oropharynx. Text in bold indicates statistically signiﬁcant risk factors.
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